203 related articles for article (PubMed ID: 18227370)
41. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Cushman WC; Ford CE; Einhorn PT; Wright JT; Preston RA; Davis BR; Basile JN; Whelton PK; Weiss RJ; Bastien A; Courtney DL; Hamilton BP; Kirchner K; Louis GT; Retta TM; Vidt DG;
J Clin Hypertens (Greenwich); 2008 Oct; 10(10):751-60. PubMed ID: 19090876
[TBL] [Abstract][Full Text] [Related]
42. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.
Davis BR; Cutler JA; Gordon DJ; Furberg CD; Wright JT; Cushman WC; Grimm RH; LaRosa J; Whelton PK; Perry HM; Alderman MH; Ford CE; Oparil S; Francis C; Proschan M; Pressel S; Black HR; Hawkins CM
Am J Hypertens; 1996 Apr; 9(4 Pt 1):342-60. PubMed ID: 8722437
[TBL] [Abstract][Full Text] [Related]
43. Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome?
Grimm RH; Davis BR; Piller LB; Cutler JA; Margolis KL; Barzilay J; Dart RA; Graumlich JF; Murden RA; Randall OS;
J Clin Hypertens (Greenwich); 2009 Sep; 11(9):466-74. PubMed ID: 19751458
[TBL] [Abstract][Full Text] [Related]
44. Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Pressel SL; Davis BR; Wright JT; Geraci TS; Kingry C; Ford CE; Piller LB; Bettencourt J; Kimmel B; Lusk C; Parks H; Simpson LM; Nwachuku C; Furberg CD;
Control Clin Trials; 2001 Feb; 22(1):29-41. PubMed ID: 11165421
[TBL] [Abstract][Full Text] [Related]
45. Thiazide and loop diuretics.
Sica DA; Carter B; Cushman W; Hamm L
J Clin Hypertens (Greenwich); 2011 Sep; 13(9):639-43. PubMed ID: 21896142
[TBL] [Abstract][Full Text] [Related]
46. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial.
Davis BR; Cutler JA; Furberg CD; Wright JT; Farber MA; Felicetta JV; Stokes JD;
Ann Intern Med; 2002 Sep; 137(5 Part 1):313-20. PubMed ID: 12204014
[TBL] [Abstract][Full Text] [Related]
47. Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Papademetriou V; Piller LB; Ford CE; Gordon D; Hartney TJ; Geraci TS; Reisin E; Sumner BM; Wong ND; Nwachuku C; Narayan P; Haywood J; Habib G;
J Clin Hypertens (Greenwich); 2003; 5(6):377-84. PubMed ID: 14688492
[TBL] [Abstract][Full Text] [Related]
48. Recommendations for the management of special populations: racial and ethnic populations.
Ferdinand KC
Am J Hypertens; 2003 Nov; 16(11 Pt 2):50S-54S. PubMed ID: 14625162
[TBL] [Abstract][Full Text] [Related]
49. Alpha-blockers and congestive heart failure: early termination of an arm of the ALLHAT trial.
Vidt DG
Cleve Clin J Med; 2000 Jun; 67(6):429-33. PubMed ID: 10860225
[TBL] [Abstract][Full Text] [Related]
50. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Cushman WC; Davis BR; Pressel SL; Cutler JA; Einhorn PT; Ford CE; Oparil S; Probstfield JL; Whelton PK; Wright JT; Alderman MH; Basile JN; Black HR; Grimm RH; Hamilton BP; Haywood LJ; Ong ST; Piller LB; Simpson LM; Stanford C; Weiss RJ;
J Clin Hypertens (Greenwich); 2012 Jan; 14(1):20-31. PubMed ID: 22235820
[TBL] [Abstract][Full Text] [Related]
51. Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Muntner P; Levitan EB; Lynch AI; Simpson LM; Whittle J; Davis BR; Kostis JB; Whelton PK; Oparil S
J Clin Hypertens (Greenwich); 2014 May; 16(5):323-30. PubMed ID: 24739073
[TBL] [Abstract][Full Text] [Related]
52. Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone.
Piller LB; Davis BR; Cutler JA; Cushman WC; Wright JT; Williamson JD; Leenen FH; Einhorn PT; Randall OS; Golden JS; Haywood LJ;
Curr Control Trials Cardiovasc Med; 2002 Nov; 3(1):10. PubMed ID: 12459039
[TBL] [Abstract][Full Text] [Related]
53. Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT.
Piller LB; Simpson LM; Baraniuk S; Habib GB; Rahman M; Basile JN; Dart RA; Ellsworth AJ; Fendley H; Probstfield JL; Whelton PK; Davis BR;
J Gen Intern Med; 2014 Nov; 29(11):1475-83. PubMed ID: 25002161
[TBL] [Abstract][Full Text] [Related]
54. [Clinical study of the month. Which initial antihypertensive? Results from the ALLHAT trial].
Scheen AJ; Krzesinski JM
Rev Med Liege; 2003 Jan; 58(1):47-52. PubMed ID: 12647599
[TBL] [Abstract][Full Text] [Related]
55. The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Juraschek SP; Simpson LM; Davis BR; Shmerling RH; Beach JL; Ishak A; Mukamal KJ
J Hypertens; 2020 May; 38(5):954-960. PubMed ID: 31977576
[TBL] [Abstract][Full Text] [Related]
56. What ALLHAT tells us about treating high-risk patients with hypertension and hyperlipidemia.
Geraci TS; Geraci SA
J Cardiovasc Nurs; 2003; 18(5):389-95. PubMed ID: 14680343
[TBL] [Abstract][Full Text] [Related]
57. Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study.
Irvin MR; Lynch AI; Kabagambe EK; Tiwari HK; Barzilay JI; Eckfeldt JH; Boerwinkle E; Davis BR; Ford CE; Arnett DK
J Hypertens; 2010 Oct; 28(10):2076-83. PubMed ID: 20577119
[TBL] [Abstract][Full Text] [Related]
58. Clinical and demographic correlates of medication and visit adherence in a large randomized controlled trial.
Whittle J; Yamal JM; Williamson JD; Ford CE; Probstfield JL; Beard BL; Marginean H; Hamilton BP; Suhan PS; Davis BR;
BMC Health Serv Res; 2016 Jul; 16():236. PubMed ID: 27391223
[TBL] [Abstract][Full Text] [Related]
59. [Established blood pressure drug wins out in a comparative study. In hypertension, a diuretic first!].
Wepner U
MMW Fortschr Med; 2003 Jan; 145(1-2):10-2. PubMed ID: 12638431
[No Abstract] [Full Text] [Related]
60. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Haywood LJ; Ford CE; Crow RS; Davis BR; Massie BM; Einhorn PT; Williard A;
J Am Coll Cardiol; 2009 Nov; 54(22):2023-31. PubMed ID: 19926008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
